Generate:Biomedicines

Generate:Biomedicines applies generative AI and machine learning to design novel protein therapeutics from scratch. The company's platform, anchored by the Chroma generative model for protein structure, integrates computational design with high-throughput experimental validation. Backed by Flagship Pioneering with approximately $700M in total funding, Generate has established a major partnership with Novartis worth over $1B in potential milestones and is advancing approximately 20 programs across its portfolio.

~20 programs in portfolio

$700M+

Total raised

Generative AI platform for de novo protein therapeutic design. Chroma is a generative model for protein structure that can design entirely new proteins with specified properties. The platform integrates ML-based design with high-throughput experimental validation across antibodies and other protein modalities.